Outlook Therapeutics ( OTLK ) has had a pretty rough 2025. The company, despite having Lytenava approved in the UK and EU, has struggled in recent years to get the FDA on their side. So far, it has resultedI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation for the rigor ...